For example, in recent years targetable fusions have been identified with high frequency in select pediatric tumors (i.e. NTRK‐fusions in infantile fibrosarcoma and mesoblastic nephromas or ALK/ROS1/NTRK3 fusions in infantile myofibroblastic tumors).13, 14, 15, 16. The gene discussed is ROS1; the disease is mesoblastic nephroma.